Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Fatigue May Be Most Under-recognized, Undertreated Cancer-related Symptom

March 1, 1997
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 3
Volume 6
Issue 3

NEW YORK--Fatigue is a significant problem experienced by the vast majority of cancer patients--and also the most under-recognized and under-treated symptom, Barbara F. Piper, DNsc, RN, OCN, told Oncology News International in a telephone interview.

NEW YORK--Fatigue is a significant problem experienced by the vast majorityof cancer patients--and also the most under-recognized and under-treatedsymptom, Barbara F. Piper, DNsc, RN, OCN, told Oncology News Internationalin a telephone interview.

In a separate interview, William Breitbart, MD, of Memorial Sloan-Kettering,explained that fatigue may be mistaken for depression and treated inappropriately.

Dr. Piper, associate professor of nursing, University of Nebraska MedicalCenter, Omaha, stressed that cancer-related fatigue is not a 'trivial'symptom without serious sequelae.

Psychological studies have found that cancer patients experiencing fatigueare significantly more functionally impaired, depressed, distressed, andhopeless than patients without fatigue, and are more likely to have thoughtsof suicide.

Moreover, she pointed out, three retrospective clinical studies in patientswith malignant melanoma, lung cancer, and breast cancer suggest that highfatigue levels at diagnosis may be predictive of poor treatment responseand poor long-term outcome.

"Cancer-related fatigue is multicausal and multidimensional,"Dr. Piper said, adding to the difficulty in assessing and treating theproblem. She has developed the Piper Fatigue Scale, which condenses thedimensions of fatigue into four sub-scales: affective meaning, sensory,cognitive/mood, and behavioral/severity.

This scale is being used at several major cancer centers to help physicians,nurses, and psychosocial health care personnel assess the causes and intensityof their patients' fatigue as a rational basis for treatment.

Dr. Piper pointed out that functional impairment--difficulties in performingvirtually all daily activities (dressing, showering, walking, housekeeping,talking, concentrating, decision making, working)--is a common and distressingphysical manifestation of cancer-related fatigue.

Functional impairment can lead to manifestations of emotional distress,ranging from anxiety and feelings of hopelessness to behavioral changes,depression, and even self-destructive ideation, she said.

Patients with newly diagnosed early-stage breast cancer often have moresevere fatigue than those with recurrent disease, she said, possibly becausenewly diagnosed patients have not yet learned the skills for coping withthe emotional stress of a cancer diagnosis, with treatment-associated fatigue,and with the prospect of potential disease recurrence.

The Sixth Vital Sign?

Dr. Piper proposed that fatigue should be incorporated into every medicalhistory and physical exam as the sixth vital sign. "Often," shesaid, "the cancer patient will not volunteer fatigue symptoms, feelingthat the physician or health care provider should not be bothered with'trivia.'"

She urged physicians and nurses to bring the question out into the open,"regardless of whether or not your patient complains of fatigue orappears fatigued. Tell your patient that fatigue is important and thatyou are interested in assessing and validating it."

Medical causes of fatigue must be treated before other dimensions offatigue can be assessed and addressed. Dr. Piper pointed out that the frequencyand intensity of fatigue may be affected by a number of medical conditions(Table 1).

TABLE 1: Medical Conditions That Are a PotentialCause of Cancer-Related Fatigue

"Treatment of these conditions such as with blood transfusions,erythropoietin, or nutritional supplements may improve hemoglobin levelsand tissue oxygenation status, thereby reducing fatigue and improving functionalability," Dr. Piper said.

Management of other treatment-related medical symptoms (eg, nausea,vomiting, diarrhea, neurologic pain) may also impact positively on fatigue,she said.

Many physicians consider cancer related fatigue to be a manifestationof clinical depression. Actually, however, cancer-related fatigue and clinicaldepression are two discrete syndromes,

William Breitbart, MD, said in a telephone interview. He is associateattending psychiatrist and chief of the Psychiatry Service at MemorialSloan-Kettering Cancer Center.

In a large-scale NIH-supported study, Dr. Breitbart has used seven differentscales to grade fatigue, physical distress, psychological distress, andperformance status in patients with AIDS who had severe fatigue.

He told Oncology News International that about half of his patientswho experienced severe fatigue had no measurable clinical depression. Evenin those patients who had both fatigue and clinical depression, he said,many severe fatigue items could not be accounted for by depression itemsin the scales.

Helping Patients Cope

The two investigators both emphasized that psychiatric and/or psychosocialcounseling as well as support groups can be very useful for helping thecancer patient cope with emotional stress, anxiety, conflict, depression,and social tension in the family and work environment. Dr. Piper addedthat self-help strategies (see Table 2) can do much to reduce cancer-relatedfatigue.

TABLE 2: Self-Help Strategies for Cancer PatientsWho Suffer From Fatigue

"Currently, physicians and HMOs are looking at the efficacy ofcancer therapy not only by objective response criteria but also by qualityof life indicators," Dr. Piper said. "Fatigue is certainly onesuch indicator, and should be included at least in the physical symptomlistings of quality of life instruments."

Articles in this issue

Bills Address Women's Health and Cancer Issues
Possible Evolutionary Advantage Seen in Breast Cancer Genes
Physicians Urged to Listen to Tamoxifen Users' Concerns
Neck Check Exam Aims at Early Detection
Upcoming Multicenter Study Will Compare Digital Versus Film Screen Mammography
Investigation Clears Fisher of Scientific Misconduct Charges In NSABP Studies
NCAB to Consider Mammography in Forties
Endocrinologists Issue Clinical Guidelines for Thyroid Cancer
Fatigue May Be Most Under-recognized, Undertreated Cancer-related Symptom
Hormone Replacement Therapy: Making Informed Decisions
AHCPR Issues Colorectal Cancer Screening Evidence Report
Genetic Advances Allow Early Detection of MEN Syndromes
MRI Used to Detect Local Prostate Cancer Recurrence After Prostatectomy
Proposed Budget Increase for NCI Is Below Expected Rate of Inflation
Mammography in One's 40s: Considering the Arguments
Recent Videos
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Two experts are featured in this series.
Related Content
Advertisement

Thomas Hope, MD, asserts that legislation aimed at resolving infiltration-related AEs does not address any relevant clinical issue.

HR 2541: How May Its Implementation Impact Radiation Oncology Practice?

Roman Fabbricatore
November 29th 2025
Article

Thomas Hope, MD, asserts that legislation aimed at resolving infiltration-related AEs does not address any relevant clinical issue.


Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Daniel C. McFarland, DO;Louis P. Voigt, MD;Yesne Alici, MD
November 24th 2025
Podcast

Daniel C. McFarland, DO, is joined by Louis P. Voigt, MD, and Yesne Alici, MD, who focused on decision-making capacity and patient-centered care.


Investigators noted 1 instance of rectovaginal fistula in the PEG gel arm, although rapid postoperative recovery occurred.

PEG Hydrogel Reduces Rectal Radiation During Cervical Cancer Therapy

Russ Conroy
November 27th 2025
Article

Investigators noted 1 instance of rectovaginal fistula in the PEG gel arm, although rapid postoperative recovery occurred.


Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

How Can Chlorotoxin-Directed CAR T-Cell Therapy Impact Glioblastoma Care?

Michael Barish, PhD
November 17th 2025
Podcast

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.


The regulatory decision was supported by findings from the phase 1/2 BGB-11417-201 trial, which evaluated sonrotoclax monotherapy in those with MCL.

Sonrotoclax Earns FDA Priority Review in R/R Mantle Cell Lymphoma

Roman Fabbricatore
November 26th 2025
Article

The regulatory decision was supported by findings from the phase 1/2 BGB-11417-201 trial, which evaluated sonrotoclax monotherapy in those with MCL.


177Lu/SBRT Improves PFS in Oligorecurrent Hormone-Sensitive Prostate Cancer

177Lu/SBRT Improves PFS in Oligorecurrent Hormone-Sensitive Prostate Cancer

Ariana Pelosci
November 26th 2025
Article

In the 177Lu plus SBRT arm, the median PFS was 17.6 months vs 7.4 months in the SBRT alone arm for patients with oligorecurrent HSPC.

Related Content
Advertisement

Thomas Hope, MD, asserts that legislation aimed at resolving infiltration-related AEs does not address any relevant clinical issue.

HR 2541: How May Its Implementation Impact Radiation Oncology Practice?

Roman Fabbricatore
November 29th 2025
Article

Thomas Hope, MD, asserts that legislation aimed at resolving infiltration-related AEs does not address any relevant clinical issue.


Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Daniel C. McFarland, DO;Louis P. Voigt, MD;Yesne Alici, MD
November 24th 2025
Podcast

Daniel C. McFarland, DO, is joined by Louis P. Voigt, MD, and Yesne Alici, MD, who focused on decision-making capacity and patient-centered care.


Investigators noted 1 instance of rectovaginal fistula in the PEG gel arm, although rapid postoperative recovery occurred.

PEG Hydrogel Reduces Rectal Radiation During Cervical Cancer Therapy

Russ Conroy
November 27th 2025
Article

Investigators noted 1 instance of rectovaginal fistula in the PEG gel arm, although rapid postoperative recovery occurred.


Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

How Can Chlorotoxin-Directed CAR T-Cell Therapy Impact Glioblastoma Care?

Michael Barish, PhD
November 17th 2025
Podcast

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.


The regulatory decision was supported by findings from the phase 1/2 BGB-11417-201 trial, which evaluated sonrotoclax monotherapy in those with MCL.

Sonrotoclax Earns FDA Priority Review in R/R Mantle Cell Lymphoma

Roman Fabbricatore
November 26th 2025
Article

The regulatory decision was supported by findings from the phase 1/2 BGB-11417-201 trial, which evaluated sonrotoclax monotherapy in those with MCL.


177Lu/SBRT Improves PFS in Oligorecurrent Hormone-Sensitive Prostate Cancer

177Lu/SBRT Improves PFS in Oligorecurrent Hormone-Sensitive Prostate Cancer

Ariana Pelosci
November 26th 2025
Article

In the 177Lu plus SBRT arm, the median PFS was 17.6 months vs 7.4 months in the SBRT alone arm for patients with oligorecurrent HSPC.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.